AI-Enabled Early Screening for Alzheimer's Disease: From "Subjective Assessment" to "Data Quantification"
As population aging continues to accelerate, elderly brain health has become a major public health issue concerning national well-being, family happiness, and social development.
Among these, Alzheimer's disease (AD), the most common type of cognitive impairment in older adults, is silently eroding the memory and quality of life of millions of elderly individuals, imposing a heavy physical, emotional, and financial burden on countless families.
Authoritative data from the China Alzheimer's Disease Report 2025 is alarming: the number of AD patients in China has now reached nearly 17 million, while the population at high risk due to mild cognitive impairment (MCI) is close to 40 million.
This means that tens of millions of elderly people in China are on the verge of cognitive decline, making the screening and prevention of Alzheimer's disease an urgent priority.
In daily life, there are common misconceptions about Alzheimer's disease screening.
Most people believe that memory loss, slower reaction times, and forgetfulness are just normal signs of aging and require no special attention.
It is this false sense of security that causes many high-risk individuals to miss the optimal window for early detection and intervention.
By the time patients develop obvious symptoms-such as memory loss, cognitive confusion, and reduced ability to perform daily tasks-and are diagnosed at hospitals, irreversible and permanent damage has already occurred in the nerve cells and brain tissues of key regions.
Currently, there is no specific drug in clinical medicine that can completely cure Alzheimer's disease. Once brain damage occurs, lost cognitive function cannot be restored through treatment.
This confirms the core principle of Alzheimer's prevention and control: prevention is better than treatment, and early screening is better than late intervention.
Only by adhering to early screening, early diagnosis, early intervention, and early treatment can we effectively slow cognitive decline, prevent the progression from MCI to AD, protect elderly brain health to the greatest extent, and reduce the caregiving burden on families.
Therefore, promoting early screening for Alzheimer's disease is key to addressing the challenges of elderly cognitive disease prevention and control.
Traditional cognitive screening methods mostly rely on manual interviews and paper-based assessments, which have many shortcomings and limitations.
The traditional process is cumbersome and time-consuming, requiring highly skilled medical staff. Moreover, assessment results are easily affected by subjective judgment, environmental factors, and the patient's emotional state, leading to potential inaccuracies.
At the same time, traditional screening methods struggle to detect subtle early functional abnormalities in the brain and cannot accurately predict disease risk, making it difficult to meet the needs of large-scale, routine, and precise public screening.
In this context, the application of the ADDS Cognitive Dysfunction Screening System offers a scientific, intelligent, and standardized solution for Alzheimer's disease screening.
The ADDS Cognitive Dysfunction Screening System deeply integrates internationally recognized cognitive assessment scales. Leveraging cutting-edge AI and human-computer interaction technologies, it reconstructs the standardized assessment process. It innovatively uses a dual-mode evaluation approach-voice interaction and intelligent image recognition-to achieve fully automated and standardized assessments, eliminating deviations caused by manual operations.
Throughout the interactive assessment, the system simultaneously and precisely collects dynamic EEG (electroencephalogram) signals, capturing subtle changes in brain activity from multiple angles.
Powered by a robust AI algorithm model, the system performs multi-scale deep feature analysis and intelligent filtering of the collected EEG and cognitive assessment data. This allows it to accurately identify subtle abnormal changes in cognitive function, providing objective and precise scientific evidence for clinical judgment of cognitive impairment and early screening of Alzheimer's disease risk-perfectly realizing the upgrade from "subjective assessment" to "data quantification."
Compared with traditional screening methods, the ADDS Cognitive Dysfunction Screening System offers multiple core advantages, making it better suited for routine public screening needs.
First, it is non-invasive and safe, requiring no intrusive testing and causing no pain, making it suitable for people of all ages, especially the elderly.
Second, it is highly efficient, simplifying complex procedures, greatly shortening screening time, and quickly generating assessment reports.
Third, it is scientifically accurate, relying on authoritative scales and AI big data analysis to avoid human error, ensuring objective and rigorous test results.
Fourth, it is easy to operate, featuring an intelligent human-computer interaction mode that requires no complex operations. Elderly individuals can complete the screening independently, making it suitable for various settings such as communities, health check-up centers, and medical institutions.
The data from tens of millions of high-risk individuals warns us that Alzheimer's prevention and control cannot wait for the disease to develop-we must take proactive action in advance.
Memory fades in an instant, and brain health cannot be regained once lost. Every early screening is a safeguard for elderly health and a guarantee of family happiness.
Equipped with technology as its armor, the ADDS Cognitive Dysfunction Screening System compensates for the shortcomings of traditional screening, bridges the critical gap in early Alzheimer's warning, and brings precise early screening into the daily lives of the public.
In the future, by relying on scientific and intelligent screening methods and continuously advancing public cognitive health screening, we can effectively reduce the incidence and severity of Alzheimer's disease, build a strong defense for the memory of millions of elderly people, and use the power of technology to protect their golden years.